Trial Profile

A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib monotherapy in RAS Mutant Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Biomarker; Proof of concept; Therapeutic Use
Acronyms PROSPECT-R

Most Recent Events

30 Apr 2021 Status changed from recruiting to completed.
28 Apr 2020 Results (n=43) presented at the 111th Annual Meeting of the American Association for Cancer Research - I
12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com